Chargement en cours...
How I treat relapsed or refractory AML
Treatment of relapsed or refractory acute myeloid leukemia (AML) has presented challenges for hematologists for decades. Despite numerous clinical studies, outcomes are consistently disappointing with 5-year overall survival rates of ∼10%. Allogeneic hematopoietic cell transplantation at the time of...
Enregistré dans:
| Publié dans: | Blood |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
American Society of Hematology
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7453152/ https://ncbi.nlm.nih.gov/pubmed/32518943 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019001982 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|